The University of Saskatchewan (U of S) and Sundial Growers Inc. (Sundial) have entered into a three-year memorandum of agreement to explore research opportunities involving the medicinal use of cannabis collectively.
Part of the collaboration will focus on employing cannabinoid therapy to treat dementia.
“With our wide-ranging multidisciplinary expertise and cutting-edge plant genomics research, the U of S is eager to work with Sundial to uncover the full potential of cannabis for health and economic benefits,” said U of S Vice-President of Research, Karen Chad in a press release. “This unique study is the first step in our exciting collaboration and will no doubt position the U of S as a national leader in advancing cannabis as a treatment for dementia.”
Sundial will provide U of S with a consistent supply of quality cannabis which they will utilize alongside the cannabis gene collections to which they have access.
“With today’s announcement and similar collaborations with the University of Calgary and Sundial’s Mitacs research initiative, we are demonstrating our commitment to becoming a leader in Canada with respect to cannabinoid research,” stated Sundial President Geoff Thompson. “We believe strongly in the potential of cannabis as a modern natural alternative and health solution to the many ailments.”
“We are excited to work with the University of Saskatchewan to further prove the efficacy of cannabis through rigorous scientific research and clinical testing,” he said.
The U of S chose to focus on dementia due to concerns about the impact that it is having on aging populations around the world.
